These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

189 related articles for article (PubMed ID: 7929212)

  • 21. ErbB tyrosine kinases and the two neuregulin families constitute a ligand-receptor network.
    Pinkas-Kramarski R; Shelly M; Guarino BC; Wang LM; Lyass L; Alroy I; Alimandi M; Kuo A; Moyer JD; Lavi S; Eisenstein M; Ratzkin BJ; Seger R; Bacus SS; Pierce JH; Andrews GC; Yarden Y
    Mol Cell Biol; 1998 Oct; 18(10):6090-101. PubMed ID: 9742126
    [TBL] [Abstract][Full Text] [Related]  

  • 22. The epidermal growth factor receptor couples transforming growth factor-alpha, heparin-binding epidermal growth factor-like factor, and amphiregulin to Neu, ErbB-3, and ErbB-4.
    Riese DJ; Kim ED; Elenius K; Buckley S; Klagsbrun M; Plowman GD; Stern DF
    J Biol Chem; 1996 Aug; 271(33):20047-52. PubMed ID: 8702723
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Coexpression of erbB2 and erbB3 proteins reconstitutes a high affinity receptor for heregulin.
    Sliwkowski MX; Schaefer G; Akita RW; Lofgren JA; Fitzpatrick VD; Nuijens A; Fendly BM; Cerione RA; Vandlen RL; Carraway KL
    J Biol Chem; 1994 May; 269(20):14661-5. PubMed ID: 7514177
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Heregulin-stimulated signaling in rat pheochromocytoma cells. Evidence for ErbB3 interactions with Neu/ErbB2 and p85.
    Gamett DC; Greene T; Wagreich AR; Kim HH; Koland JG; Cerione RA
    J Biol Chem; 1995 Aug; 270(32):19022-7. PubMed ID: 7642563
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Differential expression of NDF/neuregulin receptors ErbB-3 and ErbB-4 and involvement in inhibition of neuronal differentiation.
    Pinkas-Kramarski R; Eilam R; Alroy I; Levkowitz G; Lonai P; Yarden Y
    Oncogene; 1997 Dec; 15(23):2803-15. PubMed ID: 9419971
    [TBL] [Abstract][Full Text] [Related]  

  • 26. NDF/heregulin stimulates the phosphorylation of Her3/erbB3.
    Kita YA; Barff J; Luo Y; Wen D; Brankow D; Hu S; Liu N; Prigent SA; Gullick WJ; Nicolson M
    FEBS Lett; 1994 Jul; 349(1):139-43. PubMed ID: 8045292
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Formation of a high affinity heregulin binding site using the soluble extracellular domains of ErbB2 with ErbB3 or ErbB4.
    Fitzpatrick VD; Pisacane PI; Vandlen RL; Sliwkowski MX
    FEBS Lett; 1998 Jul; 431(1):102-6. PubMed ID: 9684874
    [TBL] [Abstract][Full Text] [Related]  

  • 28. The structural basis for the specificity of epidermal growth factor and heregulin binding.
    Barbacci EG; Guarino BC; Stroh JG; Singleton DH; Rosnack KJ; Moyer JD; Andrews GC
    J Biol Chem; 1995 Apr; 270(16):9585-9. PubMed ID: 7721889
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Heregulins and the ErbB-2/3/4 receptors in gliomas.
    Westphal M; Meima L; Szonyi E; Lofgren J; Meissner H; Hamel W; Nikolics K; Sliwkowski MX
    J Neurooncol; 1997 Dec; 35(3):335-46. PubMed ID: 9440030
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Tissue expression of neu differentiation factor/heregulin and its receptor complex in prostate cancer and its biologic effects on prostate cancer cells in vitro.
    Lyne JC; Melhem MF; Finley GG; Wen D; Liu N; Deng DH; Salup R
    Cancer J Sci Am; 1997; 3(1):21-30. PubMed ID: 9072304
    [TBL] [Abstract][Full Text] [Related]  

  • 31. A hierarchical network of interreceptor interactions determines signal transduction by Neu differentiation factor/neuregulin and epidermal growth factor.
    Tzahar E; Waterman H; Chen X; Levkowitz G; Karunagaran D; Lavi S; Ratzkin BJ; Yarden Y
    Mol Cell Biol; 1996 Oct; 16(10):5276-87. PubMed ID: 8816440
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Neu differentiation factor (Heregulin) activates a p53-dependent pathway in cancer cells.
    Bacus SS; Yarden Y; Oren M; Chin DM; Lyass L; Zelnick CR; Kazarov A; Toyofuku W; Gray-Bablin J; Beerli RR; Hynes NE; Nikiforov M; Haffner R; Gudkov A; Keyomarsi K
    Oncogene; 1996 Jun; 12(12):2535-47. PubMed ID: 8700512
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Activity-dependent regulation of Neu differentiation factor/neuregulin expression in rat brain.
    Eilam R; Pinkas-Kramarski R; Ratzkin BJ; Segal M; Yarden Y
    Proc Natl Acad Sci U S A; 1998 Feb; 95(4):1888-93. PubMed ID: 9465112
    [TBL] [Abstract][Full Text] [Related]  

  • 34. ErbB-2 is a common auxiliary subunit of NDF and EGF receptors: implications for breast cancer.
    Karunagaran D; Tzahar E; Beerli RR; Chen X; Graus-Porta D; Ratzkin BJ; Seger R; Hynes NE; Yarden Y
    EMBO J; 1996 Jan; 15(2):254-64. PubMed ID: 8617201
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Recombinant heregulin-Pseudomonas exotoxin fusion proteins: interactions with the heregulin receptors and antitumor activity in vivo.
    Yang D; Kuan CT; Payne J; Kihara A; Murray A; Wang LM; Alimandi M; Pierce JH; Pastan I; Lippman ME
    Clin Cancer Res; 1998 Apr; 4(4):993-1004. PubMed ID: 9563895
    [TBL] [Abstract][Full Text] [Related]  

  • 36. The oncogenic ErbB-2/ErbB-3 heterodimer is a surrogate receptor of the epidermal growth factor and betacellulin.
    Pinkas-Kramarski R; Lenferink AE; Bacus SS; Lyass L; van de Poll ML; Klapper LN; Tzahar E; Sela M; van Zoelen EJ; Yarden Y
    Oncogene; 1998 Mar; 16(10):1249-58. PubMed ID: 9546426
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Binding specificities and affinities of egf domains for ErbB receptors.
    Jones JT; Akita RW; Sliwkowski MX
    FEBS Lett; 1999 Mar; 447(2-3):227-31. PubMed ID: 10214951
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Heregulin stimulates mitogenesis and phosphatidylinositol 3-kinase in mouse fibroblasts transfected with erbB2/neu and erbB3.
    Carraway KL; Soltoff SP; Diamonti AJ; Cantley LC
    J Biol Chem; 1995 Mar; 270(13):7111-6. PubMed ID: 7535767
    [TBL] [Abstract][Full Text] [Related]  

  • 39. A potential autocrine loop between heregulin-alpha and erbB-3 receptor in human prostatic adenocarcinoma.
    Leung HY; Weston J; Gullick WJ; Williams G
    Br J Urol; 1997 Feb; 79(2):212-6. PubMed ID: 9052472
    [TBL] [Abstract][Full Text] [Related]  

  • 40. An oncogenic point mutation confers high affinity ligand binding to the neu receptor. Implications for the generation of site heterogeneity.
    Ben-Levy R; Peles E; Goldman-Michael R; Yarden Y
    J Biol Chem; 1992 Aug; 267(24):17304-13. PubMed ID: 1355090
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.